SPDR S&P BIOTECH ETF (XBI)
| Assets | $6.92B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 76.85M |
| Dividend (ttm) | $0.13 |
| Dividend Yield | 0.14% |
| Ex-Dividend Date | Jun 24, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | +10.15% |
| Volume | 6,493,107 |
| Open | 92.42 |
| Previous Close | 93.04 |
| Day's Range | 91.04 - 92.70 |
| 52-Week Low | 63.80 |
| 52-Week High | 103.52 |
| Beta | 1.21 |
| Holdings | 143 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe SPDR S&P BIOTECH ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
28.26% of assets| Name | Symbol | Weight |
|---|---|---|
| Sarepta Therapeutics, Inc. | SRPT | 3.27% |
| United Therapeutics Corporation | UTHR | 2.97% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.86% |
| Gilead Sciences, Inc. | GILD | 2.83% |
| Amgen Inc. | AMGN | 2.79% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.74% |
| Exact Sciences Corporation | EXAS | 2.72% |
| AbbVie Inc. | ABBV | 2.71% |
| Viking Therapeutics, Inc. | VKTX | 2.69% |
| Biogen Inc. | BIIB | 2.68% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 24, 2024 | $0.11478 | Jun 26, 2024 |
| Dec 18, 2023 | $0.01388 | Dec 21, 2023 |
| Jun 20, 2023 | $0.00262 | Jun 23, 2023 |
| Mar 22, 2021 | $0.040 | Mar 25, 2021 |
| Dec 21, 2020 | $0.176 | Dec 24, 2020 |
| Sep 21, 2020 | $0.08897 | Sep 24, 2020 |
News
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Final Trades: 2-Year Treasury, Trade Desk, American Express and the XBI
The Investment Committee gives you their top names to watch for the second half.
Homebuilder sentiment tumbles in May
CNBC's Rick Santelli reports on the latest economic data to cross the tape.
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
Mizuho's Jared Holz on finding opportunities in the biotech space
Jared Holz, Mizuho Securities America healthcare equity strategist, joins 'The Exchange' to discuss why he believes we are in the midst of the most pronounced biotech rally in over five years, whether...
This biotech ETF sees ‘breakout' while U.S. small-cap technology stocks lag
Hello! This week's ETF Wrap digs into the jump in biotech funds, as well as an “unusual” trend in U.S. small-cap stocks versus small-cap tech equities.
Here's why SPDR Biotech ETF (XBI) stock price is flying
The SPDR Biotech ETF (XBI) stock has surged hard in the past few weeks as investors cheer the recent FDA approvals and M&A activity in the industry. It has soared in the past four straight weeks and i...
Navigating the big run in biotech
The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.
Satori Fund's Dan Niles reveals his top tech picks for 2024
Dan Niles, Satori Fund founder and portfolio manager, joins 'Squawk Box' to discuss the state of the tech sector, 2024 outlook, his top tech picks for 2024, and more.
These ETF strategies were big winners in 2023. Here's where one CFRA analyst sees them going next year.
Hello! This is MarketWatch reporter Isabel Wang bringing you this week's ETF Wrap. In this week's edition, we look at ETF strategies that have exploded in popularity in 2023, and whether they will con...
Dr. Scott Gottlieb talks Big Pharma's buying spree
Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
Buy or bail on biotech: Here's what you need to know
Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.
Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down
Shares have gotten a boost from the Fed and from M&A.
White House vs. Big Pharma: The battle to lower prices
Mizuho's Jared Holz and BMO Capital's Evan Seigerman join 'Power Lunch' to discuss the drug pricing battle between the Biden Administration and big pharma.
Biotech Stocks Are Rallying, but the Outlook Isn't Good
The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.
How to Find the Best Biotech ETFs
The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.
It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss how Holz broadly sees the biotechnology sector, what distills the winners from losers in the healthcare space, ...